Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Year Of The Rabbit Expected To Speed Up New Drug Approvals

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's slow drug approvals, which can take as long as two years, are expected to speed up considerably in the Chinese Year of the Rabbit. China's State FDA is expected to focus on new drug approvals this year in an attempt to get through its backlog of approval registrations
Advertisement

Related Content

China Drug Approvals Up 26%, Mostly Due To Generics
Reforms In China's Center For Drug Evaluation Designed To Boost Innovation - DIA China Conference
3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome
3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
3SBio Files For Approval For Interleukin-2 NuLeusin
3SBio Files For Approval For Interleukin-2 NuLeusin
Advertisement
UsernamePublicRestriction

Register

SC076324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel